Pathology: mUC - L1 - all population; mUC - L2 - all population; mUC - L2 - PDL1 positive;
| mUC - L1 - all population | mUC - L2 - all population | mUC - L2 - PDL1 positive | ||
| KEYNOTE-361 (P vs C), 2021 | KEYNOTE-045 (all population), 2017 | KEYNOTE-045 (PDL1 CPS >10%), 2017 | ||
| pembrolizumab alone | 3 | T1 | T1 | T1 |
| Standard of Care (SoC) | 0 | T0 | T0 | T0 |